NEW YORK (GenomeWeb News) – Sequenom's former President and CEO Harry Stylli has made an arbitration demand with the company, seeking more than $1.6 million in damages.
Registering provides access to this and other free content.
Already have an account?Login Now.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.